The HemOnc Pulse

In this episode of TheHemOnc Pulse, Rahul Banerjee, MD, speaks with Francine Foss, MD, professor of medicine and dermatology at Yale School of Medicine, about the evolving landscape of T-cell lymphomas. Dr Foss discusses the unique challenges of studying and treating rare diseases such as cutaneous T-cell lymphoma and explains why real-world data are essential to closing evidence gaps. The conversation highlights the role of collaborative registries in tracking treatment patterns, outcomes, and access to care across community and academic settings. Dr Foss also shares how both clinicians and patients can participate in these efforts to strengthen research, inform future clinical trials, and improve outcomes for patients with T-cell lymphomas.

Dr. Paul G. Richardson, a leading expert in multiple myeloma from Dana-Farber, shares his insights on innovative treatment strategies involving XPO1 inhibition. He dives into the evolution of selinexor, discussing its flexible use in relapsed multiple myeloma cases, particularly how it can serve as a bridge to CAR T therapies. Dr. Richardson highlights real-world patient scenarios and emphasizes the importance of personalized treatment plans to optimize outcomes. He also reveals promising data on selinexor in combination with emerging therapies, showcasing its potential for rapid responses.

Dr. Eunice Wang, a leading expert in AML and chief of the leukemia service at Roswell Park, joins Dr. Rahul Banerjee for a deep dive into the complexities of leukemia treatment. They discuss the biology and risk profile of NPM1, and how menin inhibitors function, shedding light on the COMET-001 trial for ziftomenib. With a 33% response rate, Wang highlights its promise in treating relapsed AML. The duo also explores combinations of ziftomenib with other therapies, and details the importance of differentiating syndrome management in practice.

Dr. Omar Nadeem, a Senior Physician at Dana-Farber and Assistant Professor at Harvard, shares cutting-edge developments in smoldering myeloma. He discusses how genomic profiling can refine risk stratification and highlight high-risk patients, allowing for personalized treatment. The role of innovative models like PANGEA and AI in dynamic risk assessment is explored, alongside exciting insights into bispecific antibodies and their early successes in trials. Dr. Nadeem emphasizes the shift towards early detection and intervention strategies to improve patient outcomes.

Dr. Rahul Banerjee interviews Dr. Ajay Major on patient-reported outcomes, toxicity reporting, and patient engagement in blood cancer clinical trials.

Dr. Gabriela Hobbs, a leading hematologist and MPN researcher at Massachusetts General Hospital, shares groundbreaking insights on myeloproliferative neoplasms. She delves into the impressive results from the VERIFY trial on rusfertide, detailing its hematocrit control and safety profile. Dr. Hobbs also discusses the efficacy of ropeginterferon and its advantages over traditional treatments. Additionally, she highlights ongoing clinical trials to watch and emphasizes the pressing need for therapies addressing thrombocytopenia and disease progression.

Host Rahul Banerjee, MD, speaks with Drs. Frederik Schjesvold and Frida Askeland on myeloma trial results, relevance in the IMROZ/CEPHEUS era, and advances in treating elderly, frail patients.

MD Anderson fellows discuss AML, MRD endpoints, and evolving trial strategies in a dynamic grand rounds–style presentation.

William Wierda, MD, PhD of the University of Texas MD Anderson discusses advances in chronic lymphocytic leukemia care, from targeted therapies and resistance to immune dysfunction and prevention with Blood Cancers Today Managing Editor, Nichole Tucker.

In this Editor’s Special Episode of The HemOnc Pulse, Dr. Hira Mian of McMaster University shares expert insights on the evolving treatment landscape for multiple myeloma. From optimizing selinexor use, to understanding long-term MonumenTAL-1 data with talquetamab, to the promise of emerging trispecific antibodies, Dr. Mian highlights the biggest shifts shaping care today.